Mumps Therapeutic Market Drugs & Companies Pipeline Review H2 2014

Share Article

ReportsnReports.com adds Mumps Pipeline Review, H2 2014 market research report of 38 pages to the Mumps drugs industry research collection of its business intelligence library.

The report “Mumps Pipeline Review, H2 2014” provides comprehensive information on the therapeutic development for Mumps, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mumps and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.reportsnreports.com/reports/317540-mumps-pipeline-review-h2-2014.html .

Mumps (epidemic parotitis) is a well-known sickness of the individual types, due to the mumps viruses. Before the development of vaccination and the discharge of a vaccine, it was a typical youth sickness worldwide. It is still a essential threat to wellness in developing countries, and outbreaks still occur sometimes in civilized globe.Painful swelling of the salivary glands – typically the parotid glandular – is the most typical business presentation. Companies discussed in this Mumps therapy Pipeline market report include Beijing Tiantan Biological Products Co., Ltd., China National Pharmaceutical Group Corporation, GlaxoSmithKline plc, Prometheon Pharma, LLC, Zydus Cadila Healthcare Limited.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report “Mumps Pipeline Review, H2 2014” is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Order a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=317540 .
Reasons to buy

  •     Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  •     Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  •     Develop strategic initiatives by understanding the focus areas of leading companies
  •     Identify and understand important and diverse types of therapeutics under development for Mumps
  •     Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  •     Devise corrective measures for pipeline projects by understanding Mumps pipeline depth and focus of Indication therapeutics
  •     Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  •     Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

List of Table & Figures include in this reports are

List of Tables
Number of Products under Development for Mumps, H2 2014
Number of Products under Development for Mumps - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
Mumps - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2014
Mumps - Pipeline by China National Pharmaceutical Group Corporation, H2 2014
Mumps - Pipeline by GlaxoSmithKline plc, H2 2014
Mumps - Pipeline by Prometheon Pharma, LLC, H2 2014
Mumps - Pipeline by Zydus Cadila Healthcare Limited, H2 2014
Assessment by Monotherapy Products, H2 2014
Assessment by Combination Products, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Mumps Therapeutics - Recent Pipeline Updates, H2 2014
Mumps - Dormant Projects, H2 2014

List of Figures
Number of Products under Development for Mumps, H2 2014
Number of Products under Development for Mumps - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Combination Products, H2 2014
Number of Products by Top 10 Routes of Administration, H2 2014
Number of Products by Stage and Top 10 Routes of Administration, H2 2014
Number of Products by Top 10 Molecule Types, H2 2014
Number of Products by Stage and Top 10 Molecule Types, H2 2014

Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:
ReportsnReports.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
ReportsnReports
+1 (888) 391-5441
Email >
@chinamrreport
Follow >
ReportsnReports
Like >
Follow us on
Visit website